Benfotiamine

Benfotiamine's MCAS relevance is the deficiency-correction angle. Three preclinical studies demonstrate that thiamine deficiency directly triggers mast cell degranulation in neural tissue - meaning marginal B1 status acts as an upstream trigger for the mast cell activation we're trying to quiet. Correcting that deficiency removes one potential trigger without doing pharmacological work on the mast cell itself. Benfotiamine also inhibits NF-kB activation (a central signaling pathway in mast cell biology) in lab models. The synthesized origin means no fermentation-derived contamination, which matters for sulfite-sensitive and biogenic-amine-reactive MCAS patients.

For hEDS, benfotiamine's role is mitochondrial energy support rather than direct ECM protection. Thiamine is the precursor to TPP (thiamine pyrophosphate), the cofactor for transketolase and pyruvate dehydrogenase - central enzymes in glucose metabolism and the Krebs cycle. Fibroblasts with mitochondrial dysfunction upregulate MMP-1 (the matrix-degrading enzyme), so supporting energy production at the cellular level helps keep that pathway quieter. The connective tissue protection claims for benfotiamine in diabetes models don't translate cleanly to hEDS (different pathology), so we frame it honestly as foundational mitochondrial support rather than a targeted ECM intervention.

For POTS, the strongest case is the small but real B1-deficient subset (about 6% of POTS patients, a quarter of whom respond to thiamine repletion). The mitochondrial support angle also matters for the chronic fatigue that shadows POTS for most patients. Our 150 mg dose covers daily B1 needs with headroom for marginal deficiency. We deliberately don't position it as a high-dose autonomic intervention; the recent BOND trial showed no benefit at 600 mg, so we treat the 150 mg as foundational coverage.